JPH10507177A - Ｇｆ１２０９１８ａを含む非経口医薬組成物 - Google Patents

Ｇｆ１２０９１８ａを含む非経口医薬組成物

Info

Publication number: JPH10507177A
Authority: JP; Japan
Prior art keywords: pharmaceutical composition; composition according; effective amount; safe; group
Prior art date: 1994-10-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP8512678A

Other languages

English (en)

Japanese (ja)

Inventor

トング，ウェイ−クィン

リーウェルス，ミッキー

Original Assignee

グラクソ、ウェルカム、インコーポレーテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-05

Filing date

1995-10-04

Publication date

1998-07-14

1995-10-04 Application filed by グラクソ、ウェルカム、インコーポレーテッド filed Critical グラクソ、ウェルカム、インコーポレーテッド

1998-07-14 Publication of JPH10507177A publication Critical patent/JPH10507177A/ja

Status Pending legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
UREBDLICKHMUKA-UHFFFAOYSA-N 9-fluoro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CO)(O)C1(C)CC2O UREBDLICKHMUKA-UHFFFAOYSA-N 0.000 title description 21
239000004094 surface-active agent Substances 0.000 claims abstract description 17
239000000872 buffer Substances 0.000 claims abstract description 15
238000001802 infusion Methods 0.000 claims abstract description 13
239000007924 injection Substances 0.000 claims abstract description 11
238000002347 injection Methods 0.000 claims abstract description 11
239000003085 diluting agent Substances 0.000 claims abstract description 10
238000001556 precipitation Methods 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 9
239000012453 solvate Substances 0.000 claims abstract description 9
239000003937 drug carrier Substances 0.000 claims abstract description 6
239000000203 mixture Substances 0.000 claims description 56
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
150000001875 compounds Chemical class 0.000 claims description 13
-1 polyoxyethylene Polymers 0.000 claims description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
239000008121 dextrose Substances 0.000 claims description 11
238000000034 method Methods 0.000 claims description 11
206010028980 Neoplasm Diseases 0.000 claims description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
239000002202 Polyethylene glycol Substances 0.000 claims description 8
229920001223 polyethylene glycol Polymers 0.000 claims description 8
230000036457 multidrug resistance Effects 0.000 claims description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
229920001214 Polysorbate 60 Polymers 0.000 claims description 5
238000007911 parenteral administration Methods 0.000 claims description 5
239000008215 water for injection Substances 0.000 claims description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
230000003474 anti-emetic effect Effects 0.000 claims description 4
239000002111 antiemetic agent Substances 0.000 claims description 4
239000005022 packaging material Substances 0.000 claims description 4
229920001983 poloxamer Polymers 0.000 claims description 4
SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 3
239000004359 castor oil Substances 0.000 claims description 3
235000019438 castor oil Nutrition 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
229930195712 glutamate Natural products 0.000 claims description 3
235000011187 glycerol Nutrition 0.000 claims description 3
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
229940072106 hydroxystearate Drugs 0.000 claims description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
239000010452 phosphate Substances 0.000 claims description 3
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 3
CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims description 2
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 2
229940125665 acridine carboxamide Drugs 0.000 claims description 2
150000005215 alkyl ethers Chemical class 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
230000000767 anti-ulcer Effects 0.000 claims description 2
239000000935 antidepressant agent Substances 0.000 claims description 2
229940005513 antidepressants Drugs 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 2
229960001076 chlorpromazine Drugs 0.000 claims description 2
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 2
229960004242 dronabinol Drugs 0.000 claims description 2
RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims description 2
229960000394 droperidol Drugs 0.000 claims description 2
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
229960004503 metoclopramide Drugs 0.000 claims description 2
XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical compound C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 claims description 2
GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 claims description 2
229960002967 nabilone Drugs 0.000 claims description 2
229960000762 perphenazine Drugs 0.000 claims description 2
229960000502 poloxamer Drugs 0.000 claims description 2
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims description 2
229960003111 prochlorperazine Drugs 0.000 claims description 2
OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 claims description 2
239000008227 sterile water for injection Substances 0.000 claims description 2
XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 claims description 2
229960004869 thiethylperazine Drugs 0.000 claims description 2
XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 claims description 2
229960003904 triflupromazine Drugs 0.000 claims description 2
FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 claims description 2
229960004161 trimethobenzamide Drugs 0.000 claims description 2
239000008186 active pharmaceutical agent Substances 0.000 claims 4
229940088679 drug related substance Drugs 0.000 claims 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 2
239000006184 cosolvent Substances 0.000 claims 2
125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims 2
230000000202 analgesic effect Effects 0.000 claims 1
230000001078 anti-cholinergic effect Effects 0.000 claims 1
230000001430 anti-depressive effect Effects 0.000 claims 1
230000000840 anti-viral effect Effects 0.000 claims 1
230000003115 biocidal effect Effects 0.000 claims 1
235000019441 ethanol Nutrition 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
235000013772 propylene glycol Nutrition 0.000 claims 1
239000008174 sterile solution Substances 0.000 claims 1
CCVDVQHIQPCZBN-UHFFFAOYSA-N 5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(C(N)=O)C=CC=C2C(=O)C2=C1C(OC)=CC=C2 CCVDVQHIQPCZBN-UHFFFAOYSA-N 0.000 abstract 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
229960000583 acetic acid Drugs 0.000 description 18
239000012362 glacial acetic acid Substances 0.000 description 18
239000002246 antineoplastic agent Substances 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 11
238000009472 formulation Methods 0.000 description 11
239000000243 solution Substances 0.000 description 9
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 8
229940127089 cytotoxic agent Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
238000001990 intravenous administration Methods 0.000 description 8
229940079593 drug Drugs 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
OSFCMRGOZNQUSW-UHFFFAOYSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(OC)C=CC=C2C(=O)C2=C1C(C(=O)NC1=CC=C(C=C1)CCN1CCC=3C=C(C(=CC=3C1)OC)OC)=CC=C2 OSFCMRGOZNQUSW-UHFFFAOYSA-N 0.000 description 6
241000124008 Mammalia Species 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
241000282412 Homo Species 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
230000000973 chemotherapeutic effect Effects 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
239000000047 product Substances 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 3
229940041181 antineoplastic drug Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002736 nonionic surfactant Substances 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 2
101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
229920001304 Solutol HS 15 Polymers 0.000 description 2
230000000118 anti-neoplastic effect Effects 0.000 description 2
229940034982 antineoplastic agent Drugs 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000008693 nausea Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229940127557 pharmaceutical product Drugs 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000070918 Cima Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
241000183024 Populus tremula Species 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001251 acridines Chemical class 0.000 description 1
229930183665 actinomycin Natural products 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229950010513 ditekiren Drugs 0.000 description 1
108010083220 ditekiren Proteins 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
229960003727 granisetron Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000003752 hydrotrope Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960005343 ondansetron Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical group [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
238000012856 packing Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
238000009101 premedication Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000002461 renin inhibitor Substances 0.000 description 1
229940086526 renin-inhibitors Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
SASWSEQJAITMKS-JJNNLWIXSA-N tert-butyl (2s)-2-[[(2s)-1-[[(2s)-1-[[(4s,5s,7s)-5-hydroxy-2,8-dimethyl-7-[[(2s,3s)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]p Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC=1N=CC=CC=1)C(C)C)N(C)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C)C1=CN=CN1 SASWSEQJAITMKS-JJNNLWIXSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP8512678A 1994-10-05 1995-10-04 Ｇｆ１２０９１８ａを含む非経口医薬組成物 Pending JPH10507177A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US31830894A	1994-10-05	1994-10-05
US08/318,308		1994-10-05
PCT/US1995/012952 WO1996011007A1 (en)	1994-10-05	1995-10-04	Parenteral pharmaceutical compositions containing gf120918a

Publications (1)

Publication Number	Publication Date
JPH10507177A true JPH10507177A (ja)	1998-07-14

Family

ID=23237614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP8512678A Pending JPH10507177A (ja)	1994-10-05	1995-10-04	Ｇｆ１２０９１８ａを含む非経口医薬組成物

Country Status (12)

Country	Link
EP (1)	EP0784474A2 (de)
JP (1)	JPH10507177A (de)
KR (1)	KR970705997A (de)
AU (1)	AU702519B2 (de)
BR (1)	BR9509251A (de)
CA (1)	CA2201628A1 (de)
CZ (1)	CZ104197A3 (de)
HU (1)	HUT77883A (de)
NZ (1)	NZ295546A (de)
PL (1)	PL319511A1 (de)
RU (1)	RU2157687C2 (de)
WO (1)	WO1996011007A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2000178187A (ja) *	1998-12-15	2000-06-27	Sanochemia Pharmazeutika Ag	βカロテンの水性調合物
JP2008519828A (ja) *	2004-11-12	2008-06-12	チョンクンダンファーマセウティカルコーポレイション	タクロリムスの注射
JP2013500321A (ja) *	2009-07-30	2013-01-07	サノフイ	医薬製剤
JP2014088444A (ja) *	2000-06-30	2014-05-15	Talon Therapeutics Inc	リポソーム抗新生物薬剤およびその使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ135199A3 (cs) *	1996-10-18	1999-09-15	Xenova Limited	Způsob přípravy N-/2-(dimethylamino)ethyl/akridin-4-karboxyamidu
GB9708805D0 (en)	1997-05-01	1997-06-25	Smithkline Beecham Plc	Compounds
GB9710612D0 (en) *	1997-05-23	1997-07-16	Glaxo Group Ltd	Synthesis of acridine derivatives
GB9810876D0 (en)	1998-05-20	1998-07-22	Smithkline Beecham Plc	Compounds
US5922754A (en) *	1998-10-02	1999-07-13	Abbott Laboratories	Pharmaceutical compositions containing paclitaxel
WO2000021951A1 (en)	1998-10-08	2000-04-20	Smithkline Beecham Plc	Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
DE60030283T2 (de)	1999-05-17	2007-09-20	Cancer Research Ventures Ltd.	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
US6521635B1 (en)	2000-01-20	2003-02-18	The United States Of America As Represented By The Department Of Health And Human Services	Inhibition of MXR transport by acridine derivatives
US7122201B2 (en)	2001-06-28	2006-10-17	Baxter International Inc.	Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using surfactants and amino acids
RU2205634C1 (ru) *	2002-06-18	2003-06-10	Нестерук Владимир Викторович	Лекарственное средство, обладающее противорвотным действием

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4544657A (en) *	1983-05-19	1985-10-01	Hoffmann-La Roche Inc.	Substituted isoquinolines
KR100220538B1 (ko) *	1991-01-11	1999-09-15	뮈쉘 쥐르밀	아크리딘 유도체

1995
- 1995-10-04 CZ CZ971041A patent/CZ104197A3/cs unknown
- 1995-10-04 NZ NZ295546A patent/NZ295546A/xx unknown
- 1995-10-04 JP JP8512678A patent/JPH10507177A/ja active Pending
- 1995-10-04 BR BR9509251A patent/BR9509251A/pt not_active Application Discontinuation
- 1995-10-04 AU AU38913/95A patent/AU702519B2/en not_active Ceased
- 1995-10-04 HU HU9702291A patent/HUT77883A/hu unknown
- 1995-10-04 EP EP95938184A patent/EP0784474A2/de not_active Ceased
- 1995-10-04 CA CA002201628A patent/CA2201628A1/en not_active Abandoned
- 1995-10-04 RU RU97107466/14A patent/RU2157687C2/ru active
- 1995-10-04 PL PL95319511A patent/PL319511A1/xx unknown
- 1995-10-04 KR KR1019970702223A patent/KR970705997A/ko not_active Withdrawn
- 1995-10-04 WO PCT/US1995/012952 patent/WO1996011007A1/en not_active Ceased

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2000178187A (ja) *	1998-12-15	2000-06-27	Sanochemia Pharmazeutika Ag	βカロテンの水性調合物
JP2014088444A (ja) *	2000-06-30	2014-05-15	Talon Therapeutics Inc	リポソーム抗新生物薬剤およびその使用
JP2008519828A (ja) *	2004-11-12	2008-06-12	チョンクンダンファーマセウティカルコーポレイション	タクロリムスの注射
JP2013500321A (ja) *	2009-07-30	2013-01-07	サノフイ	医薬製剤

Also Published As

Publication number	Publication date
BR9509251A (pt)	1997-10-21
EP0784474A2 (de)	1997-07-23
RU2157687C2 (ru)	2000-10-20
AU702519B2 (en)	1999-02-25
WO1996011007A1 (en)	1996-04-18
HUT77883A (hu)	1998-09-28
NZ295546A (en)	1999-01-28
PL319511A1 (en)	1997-08-18
AU3891395A (en)	1996-05-02
CA2201628A1 (en)	1996-04-18
MX9702473A (es)	1997-07-31
CZ104197A3 (en)	1997-09-17
KR970705997A (ko)	1997-11-03

Publication	Publication Date	Title
JP5670335B2 (ja)	2015-02-18	ベンダムスチン液体製剤
US6319943B1 (en)	2001-11-20	Oral formulation for paclitaxel
CN101138550B (zh)	2012-06-27	多种表面活性剂联合使用制备的混合胶束药物制剂及其制备方法
JP4890732B2 (ja)	2012-03-07	癌治療用パクリタキセル・リポソーム組成物およびその製造方法
JPH10507177A (ja)	1998-07-14	Ｇｆ１２０９１８ａを含む非経口医薬組成物
CN107810000B (zh)	2021-03-12	来氟米林的可注射药物组合物
US20130052241A1 (en)	2013-02-28	Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US11439586B2 (en)	2022-09-13	Intratumour injection formulation
JPH02115126A (ja)	1990-04-27	エトポシド溶液
KR101679380B1 (ko)	2016-11-25	두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형
WO2005021046A1 (en)	2005-03-10	Compositions and methods for delivery of biologically active agents
KR20220137019A (ko)	2022-10-11	도세탁셀의 제형
US20110130446A1 (en)	2011-06-02	Injectable taxane pharmaceutical composition
RU2236227C1 (ru)	2004-09-20	Устойчивая фармацевтическая форма противоракового препарата
TW201215412A (en)	2012-04-16	Stable pharmaceutical composition
WO2005060871A1 (en)	2005-07-07	Pharmaceutical formulations of camptothecins and process for making same
MXPA97002473A (en)	1997-12-01	Parenteral pharmaceutical compositions containing gf1209
WO2025094002A1 (en)	2025-05-08	Lurbinectedin formulation
JP2008521834A (ja)	2008-06-26	治療学的処方物
JP2025522933A (ja)	2025-07-17	メルファランを含む安定した液体医薬組成物
US20060094692A1 (en)	2006-05-04	Pharmaceutical formulations of camptothecins and process for making same
TWI246927B (en)	2006-01-11	One kind of concentrated emulsion containing Paclitaxel (taxane)
WO2026078715A1 (en)	2026-04-16	Injectable composition of aprepitant
CN1164189A (zh)	1997-11-05	含有gf120918a的非肠道药物组合物
WO2011000811A2 (en)	2011-01-06	Organic compounds

JPH10507177A - Ｇｆ１２０９１８ａを含む非経口医薬組成物 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=23237614

Family Applications (1)

Country Status (12)

Cited By (4)

Families Citing this family (10)

Family Cites Families (2)

Cited By (4)

Also Published As

Similar Documents